Medtronic Back to Normal Growth in China, CEO Says

The transcript discusses Medtronic's global business recovery post-COVID, highlighting growth in regions like China, the US, and Europe. It addresses the backlog of elective procedures and the timeline for recovery. Challenges in providing financial guidance due to COVID-19 uncertainties are noted. The transcript also covers Medtronic's product pipeline, including innovations in cardiac rhythm, neuro modulation, and robotic surgery, as well as a breakthrough hypertension therapy.

What challenges are still present that may affect financial guidance for Medtronic?

What are the new therapies that Medtronic is focusing on for growth?

How does the new breakthrough hypertension therapy aim to impact healthcare?